Algovita Spinal Cord Stimulation System Hi-Fi Study
| Status: | Recruiting | 
|---|---|
| Conditions: | Chronic Pain, Chronic Pain | 
| Therapuetic Areas: | Musculoskeletal | 
| Healthy: | No | 
| Age Range: | 18 - 75 | 
| Updated: | 4/4/2019 | 
| Start Date: | November 2, 2018 | 
| End Date: | July 2021 | 
| Contact: | Hannah Bearinger | 
| Email: | hi-fi@brightresearchpartners.com | 
| Phone: | (612) 345-4544 | 
Clinical Trial Comparing Ultra-High Versus Traditional Pulse Widths Using the ALGOVITA® SCS System High Fidelity Stimulation in the Treatment of Persistent or Recurrent Back and/or Leg Pain Following Spinal Surgery
The objective of this study is to obtain post-market clinical outcome data for the Algovita
SCS System when used on-label, according to the applicable directions for use, using high
fidelity tonic stimulation at either ultra-high pulse width or traditional pulse width for
the treatment of persistent or recurrent back and/or leg pain following spinal surgery.
			SCS System when used on-label, according to the applicable directions for use, using high
fidelity tonic stimulation at either ultra-high pulse width or traditional pulse width for
the treatment of persistent or recurrent back and/or leg pain following spinal surgery.
Inclusion Criteria:
- Patients with FBSS defined as persistent or recurrent back and/or leg pain despite one
or more anatomically successful back surgeries for the same original pain.
- Age 18-75 years old at consent.
- Targeted pain intensity of ≥ 5 out of 10 on the Baseline visit NRS.
- ODI score of 41-80 out of 100 at the Baseline visit.
- Appropriate candidate for the surgical procedure and Algovita SCS therapy based on the
clinical judgment of the investigator and the Algovita Instructions for Provider (IFP)
in the Nuvectra product manuals.
- On stable pain medications for at least 28 days prior to consent. Stable is defined as
no new or discontinued pain medications and no changes to total daily dose of any pain
medications.
- Willing and capable of providing informed consent.
- Willing and able of complying with the study-related requirements, procedures, and
visits.
- Speaks English as a primary language (as the Algovita patient manuals are only
currently available in English).
- Has adequate cognitive ability to use the subject devices (e.g., PPC, PoP), as
determined by the investigator.
Exclusion Criteria:
- Has a medical/psychological/psychiatric condition/disorder that could interfere with
study procedures as determined by the investigator.
- Has a coexisting pain condition that might confound pain ratings, as determined by the
investigator.
- Has a condition currently requiring or likely to require the use of MRI or diathermy.
- Has an existing drug pump, SCS System, or other active implantable device.
- Has any prior SCS experience.
- Pregnant or planning to become (if female and sexually active, subject must be using a
reliable form of birth control, be surgically sterile, or be at least 2 years
postmenopausal).
- For subjects with diabetes, HbA1c ≥ 8.5% as measured at the Baseline visit (or within
the 3 months prior to the Baseline visit).
- Participating in another clinical trial that could affect the outcomes or requirements
of this study as determined by the investigator.
- Involved in an injury claim under current litigation or have a pending or approved
workers compensation claim.
We found this trial at
    9
    sites
	
									1811 East Bert Kouns Industrial Loop
Shreveport, Louisiana 71105
	
			
					Shreveport, Louisiana 71105
Principal Investigator: John Noles, MD
			
						
										Phone: 318-212-3796
					Click here to add this to my saved trials
	 
  Click here to add this to my saved trials
	 
  
									2049 E 100th St
Cleveland, Ohio 44106
	
			Cleveland, Ohio 44106
(216) 444-2200
							 
					Principal Investigator: Robert Bolash, MD
			
						
										Phone: 216-444-1292
					
		Cleveland Clinic Foundation The Cleveland Clinic (formally known as The Cleveland Clinic Foundation) is a...  
  
  Click here to add this to my saved trials
	 
  
								Columbus, Ohio 43219			
	
			
					Principal Investigator: Gladstone McDowell, MD
			
						
										Phone: 614-383-6450
					Click here to add this to my saved trials
	 
  
								Newport Beach, California 92660			
	
			
					Principal Investigator: Rick Paicius, MD
			
						
										Phone: 949-644-5800
					Click here to add this to my saved trials
	 
  
								Overland Park, Kansas 66210			
	
			
					Principal Investigator: Srinivas Nalamachu, MD
			
						
										Phone: 913-396-6278
					Click here to add this to my saved trials
	 
  
								Providence, Rhode Island 02903			
	
			
					Principal Investigator: Alexios Carayannopoulos, MD
			
						
										Phone: 401-793-9177
					Click here to add this to my saved trials
	 
  
								Santa Rosa, California 95401			
	
			
					Principal Investigator: Michael Yang, MD
			
						
										Phone: 707-623-9803
					Click here to add this to my saved trials
	 
  
								Tucson, Arizona 85712			
	
			
					Principal Investigator: Efrain Cubillo, MD
			
						
										Phone: 520-318-6035
					Click here to add this to my saved trials
	